1. Home
  2. NUVL vs ATR Comparison

NUVL vs ATR Comparison

Compare NUVL & ATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.40

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Logo AptarGroup Inc.

ATR

AptarGroup Inc.

HOLD

Current Price

$115.71

Market Cap

7.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
ATR
Founded
2017
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Plastic Products
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
7.2B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
NUVL
ATR
Price
$123.40
$115.71
Analyst Decision
Strong Buy
Buy
Analyst Count
16
4
Target Price
$134.75
$170.25
AVG Volume (30 Days)
2.5M
435.1K
Earning Date
05-08-2026
04-30-2026
Dividend Yield
N/A
1.56%
EPS Growth
N/A
6.51
EPS
N/A
1.12
Revenue
N/A
$3,777,181,000.00
Revenue This Year
N/A
$5.18
Revenue Next Year
$1,239.49
$4.98
P/E Ratio
N/A
$103.48
Revenue Growth
N/A
5.42
52 Week Low
$71.14
$103.23
52 Week High
$123.62
$164.28

Technical Indicators

Market Signals
Indicator
NUVL
ATR
Relative Strength Index (RSI) 66.60 46.26
Support Level $97.71 $111.55
Resistance Level N/A $125.35
Average True Range (ATR) 4.37 2.84
MACD 1.97 0.47
Stochastic Oscillator 99.39 62.75

Price Performance

Historical Comparison
NUVL
ATR

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About ATR AptarGroup Inc.

Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.

Share on Social Networks: